Our results suggest that HSF1 activation can attenuate the sensitivity of cancer cells to chemotherapy drugs and that the inhibition of HSF1 may be a novel target for developing a sensitization strategy to NSCLC chemotherapy in the clinic. This evidence concerns the gene HSF1 and cancer.